| Literature DB >> 28737509 |
Sam Horng1,2,3, Anthony Therattil1,2,3, Sarah Moyon1,2,3,4, Alexandra Gordon1,2,3, Karla Kim1,2,3, Azeb Tadesse Argaw1,2,3, Yuko Hara1,4, John N Mariani1,2,3, Setsu Sawai1,2,3, Per Flodby5, Edward D Crandall5, Zea Borok5, Michael V Sofroniew6, Candice Chapouly1,2,3, Gareth R John1,2,3.
Abstract
Lesions and neurologic disability in inflammatory CNS diseases such as multiple sclerosis (MS) result from the translocation of leukocytes and humoral factors from the vasculature, first across the endothelial blood-brain barrier (BBB) and then across the astrocytic glia limitans (GL). Factors secreted by reactive astrocytes open the BBB by disrupting endothelial tight junctions (TJs), but the mechanisms that control access across the GL are unknown. Here, we report that in inflammatory lesions, a second barrier composed of reactive astrocyte TJs of claudin 1 (CLDN1), CLDN4, and junctional adhesion molecule A (JAM-A) subunits is induced at the GL. In a human coculture model, CLDN4-deficient astrocytes were unable to control lymphocyte segregation. In models of CNS inflammation and MS, mice with astrocyte-specific Cldn4 deletion displayed exacerbated leukocyte and humoral infiltration, neuropathology, motor disability, and mortality. These findings identify a second inducible barrier to CNS entry at the GL. This barrier may be therapeutically targetable in inflammatory CNS disease.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28737509 PMCID: PMC5531407 DOI: 10.1172/JCI91301
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808